Biotest

Biotest Liabilities

Delisted

The The Liabilities of Biotest (BIO.DE) as of Nov 22, 2026 is 903.30 M EUR. In the previous year, The Liabilities was 912.00 M EUR — a change of -0.95% (lower).

Liabilities

903.30 MEUR

YoY

-0.95%

Last updated:

In 2024, Biotest's total liabilities amounted to 903.30 M EUR, a -0.95% difference from the 912.00 M EUR total liabilities in the previous year.

The Biotest Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
630.70 M EUR
Jan 1, 2018
547.10 M EUR
Jan 1, 2019
631.50 M EUR
Jan 1, 2020
689.70 M EUR
Jan 1, 2021
723.80 M EUR
Jan 1, 2022
831.90 M EUR
Jan 1, 2023
912.00 M EUR
Jan 1, 2024
903.30 M EUR
The Biotest Liabilities history
YEARLiabilitiesYoY
903.30 MEUR-0.95%
912.00 MEUR+9.63%
831.90 MEUR+14.94%
723.80 MEUR+4.94%
689.70 MEUR+9.22%
631.50 MEUR+15.43%
547.10 MEUR-13.26%
630.70 MEUR+10.24%
572.10 MEUR+3.94%
550.40 MEUR-0.36%
552.40 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Biotest's Liabilities

Biotest's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Biotest's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Biotest's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Biotest's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Biotest’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Biotest stock

The Liabilities of Biotest is 903.30 M EUR in 2024.

The Liabilities of Biotest changed from 912.00 M EUR to 903.30 M EUR, representing a -0.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Biotest since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Biotest historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biotest

All Key Metrics — Biotest